Clinical Trial Update: A Study to Assess the Efficacy and Tolerance of HRS-2261 in Subjects With Refractory Chronic Cough [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the efficacy and tolerability of HRS-2261 in patients with chronic cough has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cough

Drugs mentioned

• HRS-2261

Snippet

Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd | Conditions: Refractory Chronic Cough | Phase 2 | Status: COMPLETED